Events
There are a few upcoming approval dates for several companies this week. Let’s take a look at the companies and their products awaiting approval.
The idea of “fake news” that has become a hallmark of the political landscape has made its way into the biotech world. Venture capitalist Tim Draper, a longtime supporter of medtech company Theranos, blames the slow demise of the company on a “hyena” reporter.
Training the next generation of scientists is a key for the future of the biotech industry and Regeneron Pharmaceuticals is taking a lead in that responsibility through its sponsorship of the Regeneron Science Talent Search.
Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
Valeant Pharmaceuticals will change its name to Bausch Health Companies Inc. in July of this year. The company will rebrand itself with the highly recognizable name of its subsidiary eye-care company Bausch + Lomb.
Bluebird has been chosen to receive the Cooley Anemia Foundation’s Humanitarian of the Year Award at its annual gala in June.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
A biohacker who injected himself with an alleged experimental herpes vaccine before a crowded conference earlier this year was found dead in a Washington, D.C. sensory deprivation tank and the conspiracy theorists are running wild.
Birmingham, Alabama resident Emily H. will be able to pursue her dream of studying elementary education ad Auburn University due in part to a $5,000 scholarship awarded by Vertex Pharmaceuticals.
PRESS RELEASES